#StephenChan
#StephenChan presents safety results of the phase 3b #SIERRA study of durvalumab and tremelimumab #STRIDE in patients with #HCC and poor prognosis at #ESMOGI25 #ESMOAmbassadors @myesmo.bsky.social
July 2, 2025 at 4:34 PM
#StephenChan is closing the #HCC session at #ESMOGI25 addressing the difficult topic of new medical treatment in 2025 beyond current immunotherapy options. @myesmo.bsky.social #ESMOAmbassadors
July 3, 2025 at 10:17 AM